Insider Selling: Raymond Dwek Sells 3,000 Shares of United Therapeutics Corp. Stock (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) Director Raymond Dwek sold 3,000 shares of United Therapeutics Corp. stock on the open market in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $97.33, for a total transaction of $291,990.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Shares of United Therapeutics Corp. (NASDAQ:UTHR) traded up 1.22% during mid-day trading on Thursday, hitting $97.21. The stock had a trading volume of 664,458 shares. United Therapeutics Corp. has a 52 week low of $52.98 and a 52 week high of $116.65. The stock has a 50-day moving average of $107.3 and a 200-day moving average of $87.66. The company has a market cap of $4.882 billion and a price-to-earnings ratio of 17.45. United Therapeutics Corp. also saw a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 6,166,867 shares, a decline of 26.3% from the December 31st total of 7,791,595 shares. Based on an average daily trading volume, of 726,990 shares, the short-interest ratio is currently 8.5 days. Currently, 13.4% of the company’s stock are sold short.
A number of research firms have recently commented on UTHR. Analysts at Zacks upgraded shares of United Therapeutics Corp. from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, January 24th. They now have a $135.00 price target on the stock. Separately, analysts at Argus raised their price target on shares of United Therapeutics Corp. from $120.00 to $130.00 in a research note to investors on Tuesday, December 31st. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Finally, analysts at Jefferies Group raised their price target on shares of United Therapeutics Corp. from $76.00 to $91.00 in a research note to investors on Tuesday, December 24th. They now have a “hold” rating on the stock. Eight equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $91.07.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.